{1-[2-(4-Ethoxy-phenyl)-ethyl]-piperidin-4-yl}-[1-(4-fluoro-benzyl)-1H-benzoimidazol-2-yl]-amine | 73735-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: {1-[2-(4-Ethoxy-phenyl)-ethyl]-piperidin-4-yl}-[1-(4-fluoro-benzyl)-1H-benzoimidazol-2-yl]-amine
• 英文别名: N-[1-[2-(4-ethoxyphenyl)ethyl]piperidin-4-yl]-1-[(4-fluorophenyl)methyl]benzimidazol-2-amine
• CAS: 73735-39-4
• 化学式: C₂₉H₃₃FN₄O
• 分子量: 472.606
• InChiKey: LQDTUXYUHTZSFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.74
• 重原子数：
  35.0
• 可旋转键数：
  9.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  42.32
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  4-氟氯苄 在 氢溴酸 、 sodium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 {1-[2-(4-Ethoxy-phenyl)-ethyl]-piperidin-4-yl}-[1-(4-fluoro-benzyl)-1H-benzoimidazol-2-yl]-amine
  参考文献：
  名称：

  新的抗组胺N-杂环4-哌啶胺。2. 1-[（（4-氟苯基）甲基] -N-（4-哌啶基）-1H-苯并咪唑-2-a的合成及抗组胺活性。

  摘要：

  描述了一系列的1-[（4-氟苯基）甲基] -N-（4-哌啶基）-1H-苯并咪唑-2-酰胺的合成及其在体内的抗组胺活性的初步评估。通过不同的合成方法从1、4、10或55开始获得标题化合物。苯并咪唑环（84-87）的苯基核上的取代是通过两种不同的方法实现的。口服和/或皮下给药后，通过化合物48/80在大鼠中的致死性试验和豚鼠中抗组胺的致死性试验评估体内抗组胺活性。在豚鼠中研究了三种化合物（4、51和55）的作用持续时间。化合物51“阿司咪唑”，在组胺和5-羟色胺诱导的皮肤反应以及大鼠的散瞳活性方面也进行了研究，并在各种系统中测试了与组胺拮抗作用无关的周围和中枢作用。已选择阿司咪唑用于临床研究。

  DOI：

  10.1021/jm00150a029

文献信息

• METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：Thompson Todd A.

  公开号：US20110224141A1

  公开（公告）日：2011-09-15

  A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.
• US8835506B2
  申请人：——

  公开号：US8835506B2

  公开（公告）日：2014-09-16
• US9326974B2
  申请人：——

  公开号：US9326974B2

  公开（公告）日：2016-05-03
• [EN] METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER<br/>[FR] PROCÉDÉS ET COMPOSITIONS ASSOCIÉES POUR LE TRAITEMENT DU CANCER
  申请人：STC UNM

  公开号：WO2009148623A2

  公开（公告）日：2009-12-10

  A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.
• New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amines
  作者：Frans Janssens、Joseph Torremans、Marcel Janssen、Raymond A. Stokbroekx、Marcel Luyckx、Paul A. J. Janssen

  DOI：10.1021/jm00150a029

  日期：1985.12

  The synthesis of a series of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-ami nes and the preliminary evaluation of their in vivo antihistamine activity are described. The title compounds were obtained starting from either 1, 4, 10, or 55 by different synthetic methods. Substitution on the phenyl nucleus of the benzimidazole ring (84-87) was achieved by two different approaches. The

  描述了一系列的1-[（4-氟苯基）甲基] -N-（4-哌啶基）-1H-苯并咪唑-2-酰胺的合成及其在体内的抗组胺活性的初步评估。通过不同的合成方法从1、4、10或55开始获得标题化合物。苯并咪唑环（84-87）的苯基核上的取代是通过两种不同的方法实现的。口服和/或皮下给药后，通过化合物48/80在大鼠中的致死性试验和豚鼠中抗组胺的致死性试验评估体内抗组胺活性。在豚鼠中研究了三种化合物（4、51和55）的作用持续时间。化合物51“阿司咪唑”，在组胺和5-羟色胺诱导的皮肤反应以及大鼠的散瞳活性方面也进行了研究，并在各种系统中测试了与组胺拮抗作用无关的周围和中枢作用。已选择阿司咪唑用于临床研究。